openPR Logo
Press release

MicroRNA Tools Market Estimated to Flourish by 2023

04-14-2017 02:47 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

MicroRNA, referred as miRNA is a class of naturally occurring, small non-coding RNA molecule, which is found in plants, some of the viruses and animals. Over the past decade, it has become gradually clearer that it plays an important role in the regulation of gene. Within 10 years of research has evolved from discovering the presence of miRNA in mammals to their therapeutic applications in several diseases. Inherent to the fast developments and overall excitement surrounding miRNA findings is the rising need for applicable and validated experimental tools to allow the researchers to elucidate the expression and biological function of miRNA. It presents a fast growing research area with vast probability to discover the novel and exciting mechanism related to physiology and pathology. Technological developments such as bioinformatics and next generation sequencing (NGS) permitted the identification of excessive number of additional putative miRNA in different organisms in current years.

Browse Complete Report Details of this Market at: http://www.transparencymarketresearch.com/microrna-tools-market.html

The vital first step in miRNA research is detection of miRNA, governed by many regulatory checkpoints. Though it is hard to estimate the whole number of miRNA, to date, over 2000 human, miRNA are recognized and deposited in miRBase. The process of identifying miRNA is still challenging and complex and needs an interdisciplinary strategies and it should have integrational experimental approached with computational methods. Scientist can now use the advanced tools to resolve the complex findings of miRNA research.

The miRNA tools market is segmented into tools, end users and geography. The tools classified as microarrays, next generation sequencing (NGS), quantitative real time PCR (qRT-PCR), northern blotting, in situ hybridization (ISH). The Quantitative real time PCR (qRT-PCR) is known to be the largest and fastest growing segment in this market. The end users covered are biotech companies, academic and research institutes. Based on the geography, miRNA market segmentation is North America, Europe Asia Pacific, Latin America, and Middle East and Africa. United States reported to have the largest share in miRNA market followed by Europe. Due to the increased investment by foreign countries in China and India expected to be the fastest growing countries in the miRNA research tools market

The miRNA research, driven by its therapeutic and diagnostic potential has fueled the growth of global miRNA tools market. The recent developments in the molecular biology and genomic technologies will uplift the market. Moreover higher research funding, increased outsourcing to contract research in developed countries and increased investments by the foreign countries in the developing nation such as China, India etc. will create an opportunity and drive the miRNA tools market. High cost involved in the manufacturing of research tools and the lack of experienced professionals will be responsible to restrain the growth of the market.

Obtain the Sample PDF Research Report for this Market at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11111

Some of the major players in the microRNA research tools market are Affymetrix, Agilent Technologies, Exiqon A/S, Illuminia, Life Technologies Corporation, Phalanx Biotech Group, Qiagen NV, Roche Holding AG and Thermo Fisher Scientific Inc.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release MicroRNA Tools Market Estimated to Flourish by 2023 here

News-ID: 502841 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and